Gene · 26524
Papers2,966
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 2,966
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Melittin inactivates YAP/HIF-1α pathway via up-regulation of LATS2 to inhibit hypoxia-induced proliferation, glycolysis and angiogenesis in NSCLC. | Clinics (Sao Paulo) | 2024 | 38889502 | PubTator, text mining | PubMed |
| Zinc finger protein 367 exerts a cancer-promoting role in small cell lung cancer by influencing the CIT/LATS2/YAP signaling cascade. | Toxicol Appl Pharmacol | 2024 | 38880190 | PubTator, text mining | PubMed |
| NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity. | NPJ Precis Oncol | 2024 | 38879686 | PubTator, text mining | PubMed |
| Exploring the role of tRNA-derived small RNAs (tsRNAs) in disease: implications for HIF-1 pathway modulation. | J Mol Med (Berl) | 2024 | 38850298 | PubTator, text mining | PubMed |
| Hippo-YAP/TAZ signalling coordinates adipose plasticity and energy balance by uncoupling leptin expression from fat mass. | Nat Metab | 2024 | 38811804 | PubTator, text mining | PubMed |
| Regulation of Hippo-YAP signaling axis by Isoalantolactone suppresses tumor progression in cholangiocarcinoma. | Transl Oncol | 2024 | 38797019 | PubTator, text mining | PubMed |
| PAX8-AS1/microRNA-25-3p/LATS2 regulates malignant progression of ovarian cancer via Hippo signaling. | Mutat Res | 2024 | 38788314 | PubTator, text mining | PubMed |
| Blockade of a novel MAP4K4-LATS2-SASH1-YAP1 cascade inhibits tumorigenesis and metastasis in luminal breast cancer. | J Biol Chem | 2024 | 38657867 | PubTator, text mining | PubMed |
| The possible correlation between miR-762, Hippo signaling pathway, TWIST1, and SMAD3 in lung cancer and chronic inflammatory diseases. | Sci Rep | 2024 | 38589525 | PubTator, text mining | PubMed |
| A LATS2 and ALKBH5 positive feedback loop supports their oncogenic roles. | Cell Rep | 2024 | 38568805 | PubTator, text mining | PubMed |
| STUB1 is acetylated by KAT5 and alleviates myocardial ischemia-reperfusion injury through LATS2-YAP-β-catenin axis. | Commun Biol | 2024 | 38561411 | PubTator, text mining | PubMed |
| JCAD deficiency delayed liver regenerative repair through the Hippo-YAP signalling pathway. | Clin Transl Med | 2024 | 38509842 | PubTator, text mining | PubMed |
| GALNT2 targeted by miR-139-5p promotes proliferation of clear cell renal cell carcinoma via inhibition of LATS2 activation. | Discov Oncol | 2024 | 38478152 | PubTator, text mining | PubMed |
| Nomogram model including LATS2 expression was constructed to predict the prognosis of advanced gastric cancer after surgery. | World J Gastrointest Surg | 2024 | 38463354 | PubTator, text mining | PubMed |
| The significance of Hippo pathway protein expression in oral squamous cell carcinoma. | Front Med (Lausanne) | 2024 | 38444414 | PubTator, text mining | PubMed |
| Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib. | Sci Rep | 2024 | 38368446 | PubTator, text mining | PubMed |
| HERC6 regulates STING activity in a sex-biased manner through modulation of LATS2/VGLL3 Hippo signaling. | iScience | 2024 | 38327798 | PubTator, text mining | PubMed |
| APOB is a potential prognostic biomarker in hepatocellular carcinoma. | Discov Oncol | 2024 | 38310202 | PubTator, text mining | PubMed |
| Mitochondrial dynamics and colorectal cancer biology: mechanisms and potential targets. | Cell Commun Signal | 2024 | 38302953 | PubTator, text mining | PubMed |
| Enhancing protein production and growth in chinese hamster ovary cells through miR-107 overexpression. | AMB Express | 2024 | 38302631 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/26524/papers?page=6